​Pharmacology - Sirolimus

​Pharmacology - Sirolimus
Restricts the generation of immunoglobulin and inhibits the clonal growth of T cells and, more specifically, B cells during the immune response.

Method of Operation 
By attaching to a cytosolic protein known as FK-binding protein 12, it inhibits the response of precursor cells to interleukin-2 (IL-2) and, as a result, prevents the activation of T and B cells.

Orally administered; metabolized by P450 3A in the liver; hence, several medication interactions resulting from this

Use in Clinical Settings 
This medication is typically administered in conjunction with glucocorticoids or ciclosporin in order to avoid the rejection of organ transplants, particularly renal transplants, because, unlike ciclosporin, it does not cause renal damage.

Adverse Effects
A number of symptoms, including myelosuppression (which is significant), hyperlipidemia, venous thromboembolism, diarrhea, dermatitis, and osteonecrosis.
It is necessary to keep an eye on the levels of the drug in the blood.